» Articles » PMID: 15100223

Effects of Neprilysin Chimeric Proteins Targeted to Subcellular Compartments on Amyloid Beta Peptide Clearance in Primary Neurons

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Apr 22
PMID 15100223
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Neprilysin (NEP) is a rate-limiting amyloid beta peptide (Abeta)-degrading enzyme in the brain. We demonstrated previously that overexpression of neprilysin in primary cortical neurons remarkably decreased not only extracellular but also intracellular Abeta levels. To investigate the subcellular compartments where neprilysin degrades Abeta most efficiently, we expressed neprilysin chimeric proteins containing various subcellular compartment-targeting domains in neurons. Sec12-NEP, beta-galactoside alpha2,6-sialyltransferase-NEP, transferrin receptor-NEP, and growth-associated protein 43-NEP were successfully sorted to the endoplasmic reticulum, trans-Golgi network, early/recycling endosomes, and lipid rafts, respectively. We found that intracellularly, wild-type neprilysin and all the chimeras showed equivalent Abeta40-degrading activities. Abeta40 was more effectively cleared than Abeta42, and this tendency was greater for intracellular Abeta than for extracellular Abeta. Wild-type and trans-Golgi network-targeted ST-NEP cleared more intracellular Abeta42 than the other chimeras. Wild-type neprilysin cleared extracellular Abeta more effectively than any of the chimeras, among which endoplasmic reticulum-targeted Sec12-NEP was the least effective. These observations indicate that different intracellular compartments may be involved in the metabolism of distinct pools of Abeta (Abeta40 and Abeta42) to be retained or recycled intracellularly and to be secreted extracellularly, and that the endogenous targeting signal in wild-type neprilysin is well optimized for the overall neuronal clearance of Abeta.

Citing Articles

Neprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders.

Saxena S, Ansari S, Maurya V, Kumar S, Sharma D, Malhotra H ACS Pharmacol Transl Sci. 2024; 7(12):3645-3657.

PMID: 39698259 PMC: 11651204. DOI: 10.1021/acsptsci.4c00400.


The duality of amyloid-β: its role in normal and Alzheimer's disease states.

Azargoonjahromi A Mol Brain. 2024; 17(1):44.

PMID: 39020435 PMC: 11256416. DOI: 10.1186/s13041-024-01118-1.


Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective.

Ali N, Al-Kuraishy H, Al-Gareeb A, Alnaaim S, Alexiou A, Papadakis M J Cell Mol Med. 2023; 28(2):e17993.

PMID: 37847125 PMC: 10826440. DOI: 10.1111/jcmm.17993.


Somatostatin-evoked Aβ catabolism in the brain: Mechanistic involvement of α-endosulfine-K channel pathway.

Watamura N, Kakiya N, Nilsson P, Tsubuki S, Kamano N, Takahashi M Mol Psychiatry. 2021; 27(3):1816-1828.

PMID: 34737456 PMC: 9095489. DOI: 10.1038/s41380-021-01368-8.


N-Truncated Aβ Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease.

Bayer T Front Aging Neurosci. 2021; 13:710579.

PMID: 34489680 PMC: 8417877. DOI: 10.3389/fnagi.2021.710579.